HRP20080254A2 - Spojevi indolona koje se koriste za tretiranje kognitivnih oštećenja - Google Patents

Spojevi indolona koje se koriste za tretiranje kognitivnih oštećenja

Info

Publication number
HRP20080254A2
HRP20080254A2 HR20080254A HRP20080254A HRP20080254A2 HR P20080254 A2 HRP20080254 A2 HR P20080254A2 HR 20080254 A HR20080254 A HR 20080254A HR P20080254 A HRP20080254 A HR P20080254A HR P20080254 A2 HRP20080254 A2 HR P20080254A2
Authority
HR
Croatia
Prior art keywords
indolono
treatment
compounds used
cognitive
damages
Prior art date
Application number
HR20080254A
Other languages
English (en)
Croatian (hr)
Inventor
P. Blackburn Thomas
Original Assignee
Helicon Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics filed Critical Helicon Therapeutics
Publication of HRP20080254A2 publication Critical patent/HRP20080254A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20080254A 2005-12-09 2006-12-08 Spojevi indolona koje se koriste za tretiranje kognitivnih oštećenja HRP20080254A2 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74885105P 2005-12-09 2005-12-09
PCT/US2006/046826 WO2007070362A1 (en) 2005-12-09 2006-12-08 Indolone compounds useful to treat cognitive impairment

Publications (1)

Publication Number Publication Date
HRP20080254A2 true HRP20080254A2 (hr) 2008-09-30

Family

ID=37903540

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080254A HRP20080254A2 (hr) 2005-12-09 2006-12-08 Spojevi indolona koje se koriste za tretiranje kognitivnih oštećenja

Country Status (23)

Country Link
EP (2) EP2241316A1 (de)
JP (1) JP5336194B2 (de)
KR (1) KR20080077646A (de)
CN (1) CN101378750B (de)
AT (1) ATE480234T1 (de)
AU (1) AU2006326665B2 (de)
BG (1) BG110157A (de)
BR (1) BRPI0620034A2 (de)
CA (1) CA2633829A1 (de)
CZ (1) CZ2008423A3 (de)
DE (1) DE602006016849D1 (de)
EA (1) EA200870027A1 (de)
ES (1) ES2349675T3 (de)
HR (1) HRP20080254A2 (de)
IL (1) IL192022A0 (de)
IS (1) IS8733A (de)
MX (1) MX2008007377A (de)
NO (1) NO20083042L (de)
PL (1) PL386471A1 (de)
RS (1) RS20080257A (de)
SK (1) SK500262008A3 (de)
WO (1) WO2007070362A1 (de)
ZA (1) ZA200805285B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527324A4 (de) 2010-01-20 2013-08-07 Mitsubishi Gas Chemical Co Cyanatesterverbindung und härteprodukt daraus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK69693D0 (da) * 1993-06-14 1993-06-14 Neurosearch As Farven lilla
US20030078271A1 (en) 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
TW200410937A (en) * 2002-08-07 2004-07-01 Synaptic Pharma Corp 3-imino-2-indolones for the treatment of depression and/or anxiety
WO2004014307A2 (en) * 2002-08-07 2004-02-19 Synaptic Pharmaceutical Corporation Gal3 antagonists for the treatment of neuropathic pain
WO2004014376A1 (en) * 2002-08-07 2004-02-19 Synaptic Pharmaceutical Corporation Gal3 receptor antagonists for the treatment of affective disorders

Also Published As

Publication number Publication date
IL192022A0 (en) 2009-08-03
NO20083042L (no) 2008-09-08
WO2007070362A1 (en) 2007-06-21
PL386471A1 (pl) 2009-04-14
EA200870027A1 (ru) 2009-12-30
HK1127736A1 (en) 2009-10-02
BRPI0620034A2 (pt) 2011-10-25
ATE480234T1 (de) 2010-09-15
EP1957067A1 (de) 2008-08-20
IS8733A (is) 2008-06-20
EP2241316A1 (de) 2010-10-20
AU2006326665B2 (en) 2012-11-15
AU2006326665A1 (en) 2007-06-21
RS20080257A (sr) 2009-05-06
BG110157A (en) 2008-12-30
CN101378750A (zh) 2009-03-04
ZA200805285B (en) 2009-12-30
DE602006016849D1 (de) 2010-10-21
EP1957067B1 (de) 2010-09-08
CN101378750B (zh) 2012-07-18
JP5336194B2 (ja) 2013-11-06
SK500262008A3 (sk) 2009-03-05
KR20080077646A (ko) 2008-08-25
CA2633829A1 (en) 2007-06-21
CZ2008423A3 (cs) 2009-08-05
JP2009518431A (ja) 2009-05-07
MX2008007377A (es) 2008-10-29
ES2349675T3 (es) 2011-01-10

Similar Documents

Publication Publication Date Title
MY177001A (en) Phenothiazine compounds for treating mild cognitive impairment
WO2010036395A3 (en) Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
EA201370208A1 (ru) Формы рифаксимина и их применение
CR20130455A (es) Composiciones para el tratamiento de tumores
NO20082473L (no) Fremgangsmater, sammensetninger og sett for behandling av medisinske tilstander
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
MX2010009722A (es) Procedimiento de tratamiento del dolor cronico.
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA200971141A1 (ru) Соединения, активирующие теломеразу, и способы их применения
MX2009013082A (es) Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
EA200870019A1 (ru) Лактамовые соединения и способы их применения
ATE460164T1 (de) Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure
EA201001639A1 (ru) Композиции и способы их получения и применения
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
BRPI0819105A2 (pt) composição para o tratamento e prevenção de edema de pálpebra
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
ATE525372T1 (de) Pyrazinderivate als natriumkanalmodulatoren zur behandlung von schmerzen
DK1641456T3 (da) Gaboxadol til behandling af depression og andre affektive lidelser
ATE401088T1 (de) Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20081204

Year of fee payment: 3

AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
OBST Application withdrawn